This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) strong performance across its Animal Safety and Food Safety segments.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) owing to continued growth in the Diabetes business.
Edwards Lifesciences (EW) Gains on Innovation, Margin Growth
by Zacks Equity Research
In Edwards Lifesciences' (EW) Smart Recovery portfolio, the adoption of FloTrac and ClearSight sensors remains strong.
Integer Holdings (ITGR) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
3 Great Value Stocks to Buy Now for Steady Long-Term Growth
by Benjamin Rains
Exploring three highly-ranked value stocks with resilient businesses--(CAH), (GPK) and (BJ)--that investors might want to consider buying amid lingering inflation and for stable long-term expansion.
PacBio (PACB) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite robust Consumables revenues, PacBio (PACB) witnesses overall soft performance in the fourth quarter.
Nevro (NVRO) Q4 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.
Zacks.com featured highlights include Microchip Technology, Caterpillar, Xcel Energy, Cardinal Health and Archer-Daniels-Midland
by Zacks Equity Research
Microchip Technology, Caterpillar, Xcel Energy, Cardinal Health and Archer-Daniels-Midland are part of the Zacks screen of the Week article.
Syneos Health (SYNH) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Higher reimbursable expenses and growth in Deployment Solutions contribute to Commercial Solutions revenue growth at Syneos Health (SYNH).
Bio-Rad (BIO) Q4 Earnings Miss Estimates, Operating Margin Up
by Zacks Equity Research
Excluding COVID-related sales, Life Science revenues at Bio-Rad (BIO) increase 28.1%, primarily driven by Droplet Digital PCR, process chromatography, Western blotting and qPCR products.
Cardinal Health, Inc. (CAH) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Cardinal (CAH). This makes it worthwhile to examine what the stock has in store.
AMN Healthcare (AMN) Q4 Earnings, Revenues Beat Estimates
by Zacks Equity Research
Despite AMN Healthcare's (AMN) robust results in the majority of its segments, it records a soft overall Q4 performance.
Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips
by Zacks Equity Research
Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.
Shockwave Medical's (SWAV) Q4 Earnings Top, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues benefiting from its commitment to understand the venous system. However, dependency on the wide adoption of products is a concern.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
QuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
QuidelOrtho (QDEL) reports robust overall top-line results in fourth-quarter 2022, despite disappointing segmental and geographical performances on a reported basis.
LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
The severe foreign exchange headwind, inflationary pressure and the ongoing Ukraine/Russia crisis impact LabCorp's (LH) business performance in Q4.
Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay
by Zacks Equity Research
Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.
West Pharmaceutical (WST) Q4 Earnings Beat, Order Book Strong
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.
Here's Why You Should Add Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
5 Dividend Growth Stocks to Buy Amid Market Volatility
by Sweta Killa
Microchip Technology (MCHP), Caterpillar (CAT), Xcel Energy (XEL), Cardinal Health (CAH) and Archer-Daniels-Midland (ADM) could be compelling dividend growth picks amid market volatility.
Quest Diagnostics (DGX) New Pact to Boost Laboratory Services
by Zacks Equity Research
Quest Diagnostics' (DGX) recent agreement is intended to offer advanced and quality clinical laboratory services in the greater New York region and beyond.